文献推荐:大型III期验证性临床研究 | First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial...
AK105-302:派安普利单抗联合化疗用于NSCLC 鳞癌III期研究中实验组相比于对照组PFS延长时间和HR值分别是() A.2.5m 0.40 B.1.5m 0.5 C.2.8m 0.4 D.2m 0 点击查看答案 第3题 AK105-301:派安普利单抗联合安罗替尼用于NSCLC 非鳞癌1L研究中-开放单臂组:安罗替尼联合派安普利单抗组ORR和DCR分别是() A.57.1...